Akorn announces FDA approvals
BUFFALO GROVE -- Akorn-Strides recently announced the approvals of two FDA applications for Ondansetron Injection USP single- and multiple-dose vials. Akorn-Strides is a joint venture that was formed in 2005 by Akorn Inc. and Strides Arcolab Limited. The primary mission for the joint venture is developing generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and central nervous system medicines.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.